Human neonatal thymectomy induces altered B‐cell responses and autoreactivity

European Journal of Immunology - Tập 47 Số 11 - Trang 1970-1981 - 2017
Theo van den Broek1, Asaf Madi2, Eveline M. Delemarre1, Alvin Schadenberg3,1, Kiki Tesselaar1, José A. M. Borghans1, Stefan Nierkens1, Frank A. Redegeld4, Henny G. Otten1, Maura Rossetti5,6, Salvatore Albani5,6, Rachel Sorek7, Irun R. Cohen2, Nicolaas J. G. Jansen8,9, Femke van Wijk1
1Laboratory of Translational Immunology University Medical Center Utrecht/Wilhelmina Children's Hospital Utrecht The Netherlands
2Department of Immunology, The Weizmann Institute of Science, Rehovot, Israel
3Department of Pediatric Intensive Care Bristol Royal Hospital for Children Bristol UK
4Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
5Duke-National University of Singapore Graduate Medical School, Singapore
6SingHealth Translational Immunology and Inflammation Centre SingHealth Singapore
7ImmunArray Ltd., Rehovot, Israel
8Department of Pediatric Cardiothoracic Surgery University Medical Centre Utrecht Utrecht The Netherlands
9Department of Pediatric Intensive Care, University Medical Centre Utrecht, Utrecht, The Netherlands

Tóm tắt

AbstractAn association between T‐cell lymphopenia and autoimmunity has long been proposed, but it remains to be elucidated whether T‐cell lymphopenia affects B‐cell responses to autoantigens. Human neonatal thymectomy (Tx) results in a decrease in T‐cell numbers and we used this model to study the development of autoreactivity. Two cohorts of neonatally thymectomized individuals were examined, a cohort of young (1–5 years post‐Tx, n = 10–27) and older children (>10 years, n = 26), and compared to healthy age‐matched controls. T‐cell and B‐cell subsets were assessed and autoantibody profiling performed. Early post‐Tx, a decrease in T‐cell numbers (2.75 × 109/L vs. 0.71 × 109/L) and an increased proportion of memory T cells (19.72 vs. 57.43%) were observed. The presence of autoantibodies was correlated with an increased proportion of memory T cells in thymectomized children. No differences were seen in percentages of different B‐cell subsets between the groups. The autoantigen microarray showed a skewed autoantibody response after Tx. In the cohort of older individuals, autoantibodies were present in 62% of the thymectomized children, while they were found in only 33% of the healthy controls. Overall, our data suggest that neonatal Tx skews the autoantibody profile. Preferential expansion and preservation of Treg (regulatory T) cell stability and function, may contribute to preventing autoimmune disease development after Tx.

Từ khóa


Tài liệu tham khảo

10.1007/BF00916002

10.1111/j.1365-3083.1985.tb01916.x

10.1016/j.immuni.2012.02.006

10.1172/JCI84997

10.4049/jimmunol.1201235

10.1182/blood-2011-03-341396

10.1186/s12979-016-0058-z

10.1016/j.jaci.2013.08.030

10.1111/j.1365-2249.2008.03771.x

10.1016/S0022-5223(98)70403-9

10.1016/j.vaccine.2007.11.074

10.4049/jimmunol.176.3.1962

10.1084/jem.20021812

10.4049/jimmunol.172.1.40

10.1016/j.imlet.2004.10.022

10.1016/S0092-8674(04)00335-6

10.1073/pnas.0807743105

10.4049/jimmunol.1601884

10.1016/j.immuni.2014.10.004

10.1590/1414-431X20165209

10.1146/annurev.immunol.20.100301.064833

10.1182/blood-2009-09-243071

10.1002/art.37828

10.3109/08916934.2012.748753

10.1038/nrrheum.2013.30

10.1172/JCI29943

10.1073/pnas.0901528106

10.1016/j.it.2013.05.003

10.1016/0167-5699(86)90026-5

10.1111/j.1365-2567.2010.03245.x

10.1111/j.1538-7836.2006.01753.x

10.1093/rheumatology/kel157

10.3109/08830185.2013.809071

Ignat G. P., 2003, Information on diagnosis and management of systemic lupus erythematosus derived from the routine measurement of 8 nuclear autoantibodies, J. Rheumatol., 30, 1761

10.1016/j.jaut.2006.09.001

10.1186/ar2210

10.4049/jimmunol.165.10.5970

10.1016/j.immuni.2013.09.007

10.1002/art.25032

10.1016/j.clim.2013.02.024

10.1084/jem.192.11.1545

Jones J. L., 2009, IL‐21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath‐1H), J. Clin. Invest., 119, 2052

10.1038/icb.2013.55

10.1002/acr.20446

10.1136/ard.2006.052159

10.1007/BF00918666

10.1093/icvts/ivu343

10.1111/j.1365-2249.2004.02437.x

10.1155/2011/915864

10.1007/s100670050156

10.1093/icvts/ivt430

10.1016/S0022-3476(05)81907-9

10.1172/JCI39269

10.1007/BF00344296

10.1002/eji.201344408

10.1056/NEJMoa021933

10.1182/blood-2010-12-328187

10.1073/pnas.0404848101

10.1191/0961203306lu2328oa

10.1002/eji.201444627

10.1016/j.jim.2005.03.009